Yongduo Yu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yongduo Yu has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
Tao Zhang
The Second Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning 110847, P.R. China
11 shared publicationsZhetan Ren
Department of General Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, P.R. China
8 shared publications- Jirun Peng
Department of General Surgery, Beijing Shijitan Hospital, Capital Medical University
6 shared publications Xiaozhen Cheng
Department of Anorectal Surgery, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, Guangdong 518033, P.R. China
6 shared publicationsZhengchao Pan
Liaoning University of Traditional Chinese Medicine
5 shared publicationsHongkun Zhang
Liaoning University of Traditional Chinese Medicine
4 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 58 (6) , 1-16
Immune remodeling in inflammatory bowel disease-associated colorectal cancer: Mechanisms and immunotherapeutic implications (Review)
Inflammatory bowel disease‑associated colorectal cancer (IBD‑CRC) arises in the setting of long‑standing chronic intestinal inflammation, in which immune dysregulation cannot be readily attributed to the dominance of a single inhibitory pathway or to global immunosuppression. Persistent inflammatory signaling sustains a state of prolonged immune engagement, yet with constrained effector output, potentially compromising antitumor immune surveillance and limiting the clinical benefit of immunotherapy. The present review synthetises the accumulated knowledge on the long‑term immunological alterations induced by chronic inflammation, including the integration of immune signaling, shifts in activation thresholds, metabolic reprogramming, and functional polarization of immune cells. These changes are discussed in the context of both tumor initiation and tumor maintenance to delineate the immunological evolution of IBD‑CRC. The review further examines the relationship between inflammation‑induced response constraints and the limited efficacy of immune checkpoint inhibitors, and summarizes the mechanistic barriers to immunotherapy in IBD‑CRC. Collectively, these observations suggest that relieving inhibition through a single target may be insufficient to restore effective antitumor immunity. Finally, the potential value of natural plant‑derived interventions characterized by multi‑component, low‑intensity, and long‑term modulation is discussed, particularly with respect to reducing inflammatory burden and improving immune metabolic states, thereby providing a conceptual basis for the development of combination immunotherapeutic strategies.
- 22 October 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 58 (6) , 1-16
Open AccessImmune remodeling in inflammatory bowel disease-associated colorectal cancer: Mechanisms and immunotherapeutic implications (Review)
Inflammatory bowel disease‑associated colorectal cancer (IBD‑CRC) arises in the setting of long‑standing chronic intestinal inflammation, in which immune dysregulation cannot be readily attributed to the dominance of a single inhibitory pathway or to global immunosuppression. Persistent inflammatory signaling sustains a state of prolonged immune engagement, yet with constrained effector output, potentially compromising antitumor immune surveillance and limiting the clinical benefit of immunotherapy. The present review synthetises the accumulated knowledge on the long‑term immunological alterations induced by chronic inflammation, including the integration of immune signaling, shifts in activation thresholds, metabolic reprogramming, and functional polarization of immune cells. These changes are discussed in the context of both tumor initiation and tumor maintenance to delineate the immunological evolution of IBD‑CRC. The review further examines the relationship between inflammation‑induced response constraints and the limited efficacy of immune checkpoint inhibitors, and summarizes the mechanistic barriers to immunotherapy in IBD‑CRC. Collectively, these observations suggest that relieving inhibition through a single target may be insufficient to restore effective antitumor immunity. Finally, the potential value of natural plant‑derived interventions characterized by multi‑component, low‑intensity, and long‑term modulation is discussed, particularly with respect to reducing inflammatory burden and improving immune metabolic states, thereby providing a conceptual basis for the development of combination immunotherapeutic strategies.
- Open Access
- 27 August 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1899977
Microbiota-associated metabolic networks in gut-kidney communication and renal immune regulation: mechanisms and therapeutic potential
Kidney disease development and progression involve not only local inflammation, immune dysregulation, and fibrosis but also alterations in gut microbiota composition and metabolic function. Microbiota-associated metabolic signals connect the intestinal ecosystem, host metabolism, and the renal immune microenvironment through their associations with intestinal barrier integrity, renal tubular epithelial homeostasis, immune cell function, and inflammatory-fibrotic responses. Depending on their biological origin, receptor engagement, target-cell specificity, and disease context, these signals may either support immune homeostasis and tissue repair or contribute to persistent inflammation and tissue remodeling. Representative mediators include short-chain fatty acids, tryptophan-derived metabolites, bile acid-related signaling molecules, indoxyl sulfate, p-cresyl sulfate, trimethylamine N-oxide, succinate, and other host-microbiota-associated metabolites. Their biological effects, however, cannot be interpreted independently of renal function because circulating metabolite levels are also influenced by impaired renal clearance, systemic inflammation, dietary factors, and host metabolism. Conversely, kidney dysfunction reshapes intestinal barrier integrity, microbial ecology, and metabolic output, establishing a dynamic gut-kidney metabolic-immune feedback network. In this Review, we summarize current evidence linking microbiota-associated metabolic networks to renal immune remodeling across different kidney diseases, highlighting metabolite origin, shared target-cell responses, disease-specific and context-dependent mechanisms, and current evidence limitations. We further discuss therapeutic strategies targeting this axis and emphasize key translational challenges, including distinguishing causal metabolic drivers from secondary metabolic alterations and developing precision interventions based on metabolic and immune phenotypes.
- 27 August 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1899977
Open AccessMicrobiota-associated metabolic networks in gut-kidney communication and renal immune regulation: mechanisms and therapeutic potential
Kidney disease development and progression involve not only local inflammation, immune dysregulation, and fibrosis but also alterations in gut microbiota composition and metabolic function. Microbiota-associated metabolic signals connect the intestinal ecosystem, host metabolism, and the renal immune microenvironment through their associations with intestinal barrier integrity, renal tubular epithelial homeostasis, immune cell function, and inflammatory-fibrotic responses. Depending on their biological origin, receptor engagement, target-cell specificity, and disease context, these signals may either support immune homeostasis and tissue repair or contribute to persistent inflammation and tissue remodeling. Representative mediators include short-chain fatty acids, tryptophan-derived metabolites, bile acid-related signaling molecules, indoxyl sulfate, p-cresyl sulfate, trimethylamine N-oxide, succinate, and other host-microbiota-associated metabolites. Their biological effects, however, cannot be interpreted independently of renal function because circulating metabolite levels are also influenced by impaired renal clearance, systemic inflammation, dietary factors, and host metabolism. Conversely, kidney dysfunction reshapes intestinal barrier integrity, microbial ecology, and metabolic output, establishing a dynamic gut-kidney metabolic-immune feedback network. In this Review, we summarize current evidence linking microbiota-associated metabolic networks to renal immune remodeling across different kidney diseases, highlighting metabolite origin, shared target-cell responses, disease-specific and context-dependent mechanisms, and current evidence limitations. We further discuss therapeutic strategies targeting this axis and emphasize key translational challenges, including distinguishing causal metabolic drivers from secondary metabolic alterations and developing precision interventions based on metabolic and immune phenotypes.
- Open Access
- 29 July 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1893807
Microbial metabolic memory in inflammatory bowel disease: microbiota-derived metabolites, host–microbe reprogramming, and relapse susceptibility
Inflammatory bowel disease (IBD) is increasingly recognized as a disorder of disrupted host–microbe metabolic communication rather than a consequence of microbial dysbiosis alone. Gut microbiota-derived metabolites, including short-chain fatty acids, tryptophan derivatives, bile acid metabolites, polyamines, lactate, succinate, and trimethylamine N-oxide, act as functional mediators linking microbial ecological changes to epithelial barrier integrity, mucosal immune activation, inflammatory amplification, and tissue repair. However, most existing discussions have focused on individual metabolites or isolated immune pathways, leaving the dynamic and disease-stage-specific nature of microbial metabolic remodeling insufficiently defined. In this review, we reframe IBD pathogenesis from the perspective of microbial metabolic memory, emphasizing how persistent alterations in microbial metabolic output may imprint epithelial and immune cell responses even after clinical remission. We summarize how protective metabolite depletion and proinflammatory metabolite accumulation contribute to immune tolerance breakdown, barrier dysfunction, inflammatory propagation, extraintestinal immune manifestations, and relapse susceptibility. We further discuss how mucosal inflammation reciprocally reshapes microbial niches, oxygen tension, nutrient availability, and metabolic pathway activity, thereby establishing self-reinforcing host–microbe feedback loops. Finally, we evaluate emerging therapeutic strategies, including metabolite supplementation, blockade of proinflammatory metabolic signaling, microbiota-based metabolic remodeling, engineered probiotics, and metabolomics-guided precision interventions. This metabolic-memory framework may provide a more integrated basis for understanding IBD recurrence and for developing microbiota-targeted strategies aimed at restoring durable intestinal homeostasis.
- 29 July 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1893807
Open AccessMicrobial metabolic memory in inflammatory bowel disease: microbiota-derived metabolites, host–microbe reprogramming, and relapse susceptibility
Inflammatory bowel disease (IBD) is increasingly recognized as a disorder of disrupted host–microbe metabolic communication rather than a consequence of microbial dysbiosis alone. Gut microbiota-derived metabolites, including short-chain fatty acids, tryptophan derivatives, bile acid metabolites, polyamines, lactate, succinate, and trimethylamine N-oxide, act as functional mediators linking microbial ecological changes to epithelial barrier integrity, mucosal immune activation, inflammatory amplification, and tissue repair. However, most existing discussions have focused on individual metabolites or isolated immune pathways, leaving the dynamic and disease-stage-specific nature of microbial metabolic remodeling insufficiently defined. In this review, we reframe IBD pathogenesis from the perspective of microbial metabolic memory, emphasizing how persistent alterations in microbial metabolic output may imprint epithelial and immune cell responses even after clinical remission. We summarize how protective metabolite depletion and proinflammatory metabolite accumulation contribute to immune tolerance breakdown, barrier dysfunction, inflammatory propagation, extraintestinal immune manifestations, and relapse susceptibility. We further discuss how mucosal inflammation reciprocally reshapes microbial niches, oxygen tension, nutrient availability, and metabolic pathway activity, thereby establishing self-reinforcing host–microbe feedback loops. Finally, we evaluate emerging therapeutic strategies, including metabolite supplementation, blockade of proinflammatory metabolic signaling, microbiota-based metabolic remodeling, engineered probiotics, and metabolomics-guided precision interventions. This metabolic-memory framework may provide a more integrated basis for understanding IBD recurrence and for developing microbiota-targeted strategies aimed at restoring durable intestinal homeostasis.
- Open Access
- 9 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1857614
Mechanistic remodeling and immunoregulatory functions of the B cell–humoral immunity axis in inflammatory bowel disease
Inflammatory bowel disease (IBD) is an immune-mediated disorder characterized by chronic inflammation of the intestinal mucosa, arising from dysregulation across multiple layers of immune control. In recent years, the contribution of B cells and humoral immunity to IBD pathogenesis has gained increasing attention. B cells participate in mucosal immune regulation through differentiation, clonal expansion, and antibody production, and are closely associated with the formation and structural organization of local tertiary lymphoid structures (TLSs). Beyond antigen neutralization, antibodies can modulate inflammatory cell activation and tissue injury via Fc receptor signaling, complement activation, and immune complex–mediated responses. In parallel, intestinal barrier integrity and the extent of antigen exposure critically influence B cell activation and antibody output, forming an interconnected network of local immune processes. Therapeutic strategies targeting the B cell–humoral immunity axis are emerging, including B cell–directed therapies, modulation of antibody effector pathways, and restoration of mucosal immune function. Although accumulating evidence suggests that these approaches may confer benefits in controlling inflammation and modulating immune responses, their efficacy and applicability vary across different strategies and patient populations. In this review, we systematically integrate current evidence on B cell differentiation, local lymphoid organization, and humoral immune responses in IBD. We propose the “B cell–humoral immunity regulatory axis” as a conceptual framework to delineate mucosal immune remodeling in IBD, with the aim of advancing mechanistic understanding and informing the optimization of therapeutic interventions.
- 9 July 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1857614
Open AccessMechanistic remodeling and immunoregulatory functions of the B cell–humoral immunity axis in inflammatory bowel disease
Inflammatory bowel disease (IBD) is an immune-mediated disorder characterized by chronic inflammation of the intestinal mucosa, arising from dysregulation across multiple layers of immune control. In recent years, the contribution of B cells and humoral immunity to IBD pathogenesis has gained increasing attention. B cells participate in mucosal immune regulation through differentiation, clonal expansion, and antibody production, and are closely associated with the formation and structural organization of local tertiary lymphoid structures (TLSs). Beyond antigen neutralization, antibodies can modulate inflammatory cell activation and tissue injury via Fc receptor signaling, complement activation, and immune complex–mediated responses. In parallel, intestinal barrier integrity and the extent of antigen exposure critically influence B cell activation and antibody output, forming an interconnected network of local immune processes. Therapeutic strategies targeting the B cell–humoral immunity axis are emerging, including B cell–directed therapies, modulation of antibody effector pathways, and restoration of mucosal immune function. Although accumulating evidence suggests that these approaches may confer benefits in controlling inflammation and modulating immune responses, their efficacy and applicability vary across different strategies and patient populations. In this review, we systematically integrate current evidence on B cell differentiation, local lymphoid organization, and humoral immune responses in IBD. We propose the “B cell–humoral immunity regulatory axis” as a conceptual framework to delineate mucosal immune remodeling in IBD, with the aim of advancing mechanistic understanding and informing the optimization of therapeutic interventions.
- Open Access
- 9 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1877804
Mechanisms and therapeutic prospects of DNA methylation–mucosal innate immunity crosstalk in inflammatory bowel disease
Inflammatory bowel disease (IBD) comprises a group of chronic and relapsing intestinal inflammatory disorders whose pathogenesis and progression are closely associated with disruption of the intestinal mucosal barrier, dysregulated immune responses, and altered epigenetic regulation. The innate immune system is a central component of mucosal host defense and plays a pivotal role in pathogen recognition, inflammatory signal transduction, immune-cell functional regulation, and maintenance of barrier homeostasis. In recent years, DNA methylation has been increasingly recognized as an important mechanism contributing to the development and persistence of innate immune dysregulation in IBD by modulating the transcriptional activity of immune-related genes, inflammatory pathway genes, and barrier-function genes. Conversely, persistently activated innate immune responses may reshape DNA methylation patterns through inflammatory cytokines, oxidative stress, and signaling pathways such as NF-κB and JAK/STAT, thereby forming a dynamic bidirectional regulatory network. This review systematically summarizes the mechanisms underlying the crosstalk between DNA methylation and the innate immune system in IBD, with particular emphasis on its potential roles in inflammatory initiation, immune-cell infiltration, stabilization of pro-inflammatory phenotypes, mucosal barrier injury, inflammatory memory, and disease relapse. We further propose a conceptual framework termed the “DNA methylation–innate immunity interaction axis.” Current evidence suggests that this interaction axis may provide a new mechanistic perspective for understanding the maintenance of chronic inflammation and recurrent disease activity in IBD. It may also offer a theoretical basis for combined epigenetic–immune interventions, biomarker development, and optimization of precision therapeutic strategies. Future studies integrating single-cell omics, spatial omics, longitudinal cohorts, and functional validation are warranted to further define the cell-type specificity, stage-dependent effects, and clinical translational potential of this axis.
- 9 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1877804
Open AccessMechanisms and therapeutic prospects of DNA methylation–mucosal innate immunity crosstalk in inflammatory bowel disease
Inflammatory bowel disease (IBD) comprises a group of chronic and relapsing intestinal inflammatory disorders whose pathogenesis and progression are closely associated with disruption of the intestinal mucosal barrier, dysregulated immune responses, and altered epigenetic regulation. The innate immune system is a central component of mucosal host defense and plays a pivotal role in pathogen recognition, inflammatory signal transduction, immune-cell functional regulation, and maintenance of barrier homeostasis. In recent years, DNA methylation has been increasingly recognized as an important mechanism contributing to the development and persistence of innate immune dysregulation in IBD by modulating the transcriptional activity of immune-related genes, inflammatory pathway genes, and barrier-function genes. Conversely, persistently activated innate immune responses may reshape DNA methylation patterns through inflammatory cytokines, oxidative stress, and signaling pathways such as NF-κB and JAK/STAT, thereby forming a dynamic bidirectional regulatory network. This review systematically summarizes the mechanisms underlying the crosstalk between DNA methylation and the innate immune system in IBD, with particular emphasis on its potential roles in inflammatory initiation, immune-cell infiltration, stabilization of pro-inflammatory phenotypes, mucosal barrier injury, inflammatory memory, and disease relapse. We further propose a conceptual framework termed the “DNA methylation–innate immunity interaction axis.” Current evidence suggests that this interaction axis may provide a new mechanistic perspective for understanding the maintenance of chronic inflammation and recurrent disease activity in IBD. It may also offer a theoretical basis for combined epigenetic–immune interventions, biomarker development, and optimization of precision therapeutic strategies. Future studies integrating single-cell omics, spatial omics, longitudinal cohorts, and functional validation are warranted to further define the cell-type specificity, stage-dependent effects, and clinical translational potential of this axis.
- Open Access
- 2 June 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1853009
Gut microbiota alterations associated with anxiety and depression in inflammatory bowel disease: a systematic review of prospective cohorts and randomized trials
Background: Anxiety and depression are highly prevalent among patients with inflammatory bowel disease (IBD) and are closely associated with reduced quality of life and poor treatment adherence. The gut–brain axis has been proposed as a key mechanistic framework, with the gut microbiota playing a central role. However, findings from clinical studies remain inconsistent, and a comprehensive synthesis of the evidence is lacking. Objective: This systematic review aimed to integrate evidence from randomized controlled trials (RCTs) and prospective cohort studies to evaluate the associations between gut microbiota characteristics, microbiota-targeted interventions, and symptoms of anxiety and depression in patients with IBD. Methods: A systematic search was conducted in PubMed, Embase, the Cochrane Library, Web of Science, EBSCOhost, and Scopus. The search covered records from database inception to October 17, 2025. The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A descriptive synthesis approach was used to summarize the findings. Study quality was assessed using the Critical Appraisal Skills Programme (CASP) checklist. Results: Ten studies were included, comprising six prospective cohort studies and four RCTs. These studies included a total of 1,040 patients with IBD. Cohort studies consistently showed that anxiety and depressive symptoms were associated with reduced microbial α-diversity, enrichment of pro-inflammatory taxa, and depletion of short-chain fatty acid (SCFA)-producing bacteria. These associations persisted after adjustment for inflammatory markers. They were also observed when analyses were restricted to patients in remission. This suggests that the associations may not be fully explained by disease activity. Evidence from RCTs showed that microbiota-targeted interventions, including probiotics and fecal microbiota transplantation, modulated microbial composition and reduced anxiety and depression scores. Studies combining psychological interventions with microbiota profiling also suggested potential effects on gut microbial composition. However, the findings remain heterogeneous. Conclusion: Current evidence supports a close and potentially bidirectional association between gut microbiota dysbiosis and anxiety and depression in patients with IBD. Both microbiota-targeted interventions and psychological therapies may represent promising strategies for managing psychological comorbidities in IBD. Future large-scale, standardized longitudinal studies and randomized controlled trials are warranted to clarify directionality, test causal hypotheses, and develop personalized intervention approaches. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420251166542.
- 2 June 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1853009
Open AccessGut microbiota alterations associated with anxiety and depression in inflammatory bowel disease: a systematic review of prospective cohorts and randomized trials
Background: Anxiety and depression are highly prevalent among patients with inflammatory bowel disease (IBD) and are closely associated with reduced quality of life and poor treatment adherence. The gut–brain axis has been proposed as a key mechanistic framework, with the gut microbiota playing a central role. However, findings from clinical studies remain inconsistent, and a comprehensive synthesis of the evidence is lacking. Objective: This systematic review aimed to integrate evidence from randomized controlled trials (RCTs) and prospective cohort studies to evaluate the associations between gut microbiota characteristics, microbiota-targeted interventions, and symptoms of anxiety and depression in patients with IBD. Methods: A systematic search was conducted in PubMed, Embase, the Cochrane Library, Web of Science, EBSCOhost, and Scopus. The search covered records from database inception to October 17, 2025. The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A descriptive synthesis approach was used to summarize the findings. Study quality was assessed using the Critical Appraisal Skills Programme (CASP) checklist. Results: Ten studies were included, comprising six prospective cohort studies and four RCTs. These studies included a total of 1,040 patients with IBD. Cohort studies consistently showed that anxiety and depressive symptoms were associated with reduced microbial α-diversity, enrichment of pro-inflammatory taxa, and depletion of short-chain fatty acid (SCFA)-producing bacteria. These associations persisted after adjustment for inflammatory markers. They were also observed when analyses were restricted to patients in remission. This suggests that the associations may not be fully explained by disease activity. Evidence from RCTs showed that microbiota-targeted interventions, including probiotics and fecal microbiota transplantation, modulated microbial composition and reduced anxiety and depression scores. Studies combining psychological interventions with microbiota profiling also suggested potential effects on gut microbial composition. However, the findings remain heterogeneous. Conclusion: Current evidence supports a close and potentially bidirectional association between gut microbiota dysbiosis and anxiety and depression in patients with IBD. Both microbiota-targeted interventions and psychological therapies may represent promising strategies for managing psychological comorbidities in IBD. Future large-scale, standardized longitudinal studies and randomized controlled trials are warranted to clarify directionality, test causal hypotheses, and develop personalized intervention approaches. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420251166542.
- Open Access
- 21 April 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1828926
Microbiota–immune crosstalk in the regulation of intestinal motility in constipation
Constipation is a common functional gastrointestinal disorder with a complex pathogenesis. Traditional studies have primarily explained its development in terms of reduced intestinal motility or impaired defecatory coordination; however, these mechanisms alone cannot fully account for the multifactorial pathological processes underlying the condition. In recent years, increasing attention has been directed toward the roles of intestinal microbial dysbiosis and alterations in immune homeostasis in the development of constipation. The gut microbiota continuously interacts with the intestinal immune system through its structural components, metabolic products, and secreted molecules. These interactions modulate the mucosal immune microenvironment and participate in the regulation of intestinal motility by influencing the enteric nervous system, interstitial cells of Cajal, and smooth muscle function. Conversely, the immune system can reshape the composition and spatial distribution of the gut microbiota through mechanisms such as the mucosal barrier, immunoglobulin A, and antimicrobial peptides, thereby forming a bidirectional regulatory network. Accumulating evidence suggests that during the onset and progression of constipation, microbial dysbiosis, shifts in immune homeostasis, and abnormalities in intestinal motility may evolve through a progressively amplifying dynamic process, ultimately establishing a self-sustaining chronic cycle. In addition, microbiota-targeted interventions—including probiotics, prebiotics, and fecal microbiota transplantation—have demonstrated potential benefits in improving stool frequency and stool consistency in several clinical studies. However, the immunological mechanisms underlying these effects remain relatively underexplored. This review systematically summarizes the molecular mechanisms by which gut microbiota–immune interactions regulate intestinal motility. By integrating current evidence on disease progression and clinical studies, we propose a conceptual model of the “microbiota–immune–motility regulatory axis,” aiming to provide a new perspective for understanding the pathogenesis of constipation and for optimizing microbiota-based therapeutic strategies.
- 21 April 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1828926
Open AccessMicrobiota–immune crosstalk in the regulation of intestinal motility in constipation
Constipation is a common functional gastrointestinal disorder with a complex pathogenesis. Traditional studies have primarily explained its development in terms of reduced intestinal motility or impaired defecatory coordination; however, these mechanisms alone cannot fully account for the multifactorial pathological processes underlying the condition. In recent years, increasing attention has been directed toward the roles of intestinal microbial dysbiosis and alterations in immune homeostasis in the development of constipation. The gut microbiota continuously interacts with the intestinal immune system through its structural components, metabolic products, and secreted molecules. These interactions modulate the mucosal immune microenvironment and participate in the regulation of intestinal motility by influencing the enteric nervous system, interstitial cells of Cajal, and smooth muscle function. Conversely, the immune system can reshape the composition and spatial distribution of the gut microbiota through mechanisms such as the mucosal barrier, immunoglobulin A, and antimicrobial peptides, thereby forming a bidirectional regulatory network. Accumulating evidence suggests that during the onset and progression of constipation, microbial dysbiosis, shifts in immune homeostasis, and abnormalities in intestinal motility may evolve through a progressively amplifying dynamic process, ultimately establishing a self-sustaining chronic cycle. In addition, microbiota-targeted interventions—including probiotics, prebiotics, and fecal microbiota transplantation—have demonstrated potential benefits in improving stool frequency and stool consistency in several clinical studies. However, the immunological mechanisms underlying these effects remain relatively underexplored. This review systematically summarizes the molecular mechanisms by which gut microbiota–immune interactions regulate intestinal motility. By integrating current evidence on disease progression and clinical studies, we propose a conceptual model of the “microbiota–immune–motility regulatory axis,” aiming to provide a new perspective for understanding the pathogenesis of constipation and for optimizing microbiota-based therapeutic strategies.
- Open Access
- 26 February 2026
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 41 (1)
Effectiveness and safety of 3% polidocanol foam sclerotherapy in hemorrhoidal disease: a multicenter, prospective study
To evaluate the effectiveness and safety of 3% polidocanol foam sclerotherapy (PFS) injection under anoscopy in the treatment of hemorrhoidal disease (HD) compared with rubber band ligation (RBL). This was a multicenter, open-label, prospective, observational study that enrolled 222 patients with Goligher grade I, II, or III HD (internal or mixed), who were treated with 3% PFS or RBL, which depended on the physician's assessment and the patient's willingness. The primary endpoint was the clinical cure rate under anoscopy and clinical symptoms assessment at 4 weeks post-treatment. A total of 222 patients from 14 centers participated in the study, with 127 patients receiving PFS and 95 patients receiving RBL. Among the effectiveness analysis set (EAS), the clinical cure rate was 74.19% (69/93) in the PFS group and 83.13% (69/83) in the RBL group (P > 0.05). The PFS group showed quicker and better improvement in hemorrhage score post-treatment than the RBL group, with the mean (SD) changes from baseline in hemorrhage score of the two groups (P < 0.001) at 1, 4, and 12 weeks being -3.44 (1.99) vs. -1.70 (2.19), -3.85 (1.80) vs. -2.75 (2.02), and -3.81 (1.84) vs. -2.89 (2.10), respectively. The incidences of adverse events (AEs) were 2.36% (3/127) in the PFS group and 3.16% (3/95) in the RBL group, respectively, and no serious adverse events (SAEs) occurred in both groups. Patients treated with PFS showed similar effectiveness and safety as those treated with RBL under anoscopy, and a quick improvement trend in hemorrhage score post-treatment was observed in patients treated with PFS, but it needs further verification. This study has been registered on the website of Chinese Clinical Trial Registry ( https://www.chictr.org.cn/ ), registration number: ChiCTR2200060325.
- 26 February 2026
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 41 (1)
Open AccessEffectiveness and safety of 3% polidocanol foam sclerotherapy in hemorrhoidal disease: a multicenter, prospective study
To evaluate the effectiveness and safety of 3% polidocanol foam sclerotherapy (PFS) injection under anoscopy in the treatment of hemorrhoidal disease (HD) compared with rubber band ligation (RBL). This was a multicenter, open-label, prospective, observational study that enrolled 222 patients with Goligher grade I, II, or III HD (internal or mixed), who were treated with 3% PFS or RBL, which depended on the physician's assessment and the patient's willingness. The primary endpoint was the clinical cure rate under anoscopy and clinical symptoms assessment at 4 weeks post-treatment. A total of 222 patients from 14 centers participated in the study, with 127 patients receiving PFS and 95 patients receiving RBL. Among the effectiveness analysis set (EAS), the clinical cure rate was 74.19% (69/93) in the PFS group and 83.13% (69/83) in the RBL group (P > 0.05). The PFS group showed quicker and better improvement in hemorrhage score post-treatment than the RBL group, with the mean (SD) changes from baseline in hemorrhage score of the two groups (P < 0.001) at 1, 4, and 12 weeks being -3.44 (1.99) vs. -1.70 (2.19), -3.85 (1.80) vs. -2.75 (2.02), and -3.81 (1.84) vs. -2.89 (2.10), respectively. The incidences of adverse events (AEs) were 2.36% (3/127) in the PFS group and 3.16% (3/95) in the RBL group, respectively, and no serious adverse events (SAEs) occurred in both groups. Patients treated with PFS showed similar effectiveness and safety as those treated with RBL under anoscopy, and a quick improvement trend in hemorrhage score post-treatment was observed in patients treated with PFS, but it needs further verification. This study has been registered on the website of Chinese Clinical Trial Registry ( https://www.chictr.org.cn/ ), registration number: ChiCTR2200060325.
- Open Access
- 2 January 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1717138
Mitophagy in gastrointestinal tumors: mechanisms and new targets for immunotherapy
Gastrointestinal tumors (GITs), particularly gastric and colorectal cancers, are the leading causes of cancer-related deaths worldwide. Despite advances in screening technologies and the continuous development of treatments, which have improved early diagnosis and therapeutic interventions, the morbidity and mortality rates remain high, presenting a significant challenge to global public health. While existing treatments can extend patient survival to some degree, they are often accompanied by substantial side effects. In recent years, immunotherapy has yielded positive outcomes for some patients. However, the emergence of immune escape mechanisms has hindered treatment effectiveness. As a result, there is an urgent need for new therapeutic strategies that can address the limitations of current approaches. mitophagy, a key cellular process, has gained significant attention in cancer research. It plays an essential role in maintaining cellular energy balance and metabolic stability, and is intricately linked to crucial biological processes such as drug resistance, metastasis, invasion, and the tumor microenvironment. This article aims to provide a comprehensive review of the mechanisms underlying mitophagy, examining its role in gastrointestinal cancers, particularly in relation to cellular metabolism, apoptosis, drug resistance, metastasis, invasion, and the tumor microenvironment. Additionally, it will explore the potential of mitophagy as a therapeutic target and address current clinical challenges. It is hoped that this research will offer new insights and directions for the treatment of GITs.
- 2 January 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1717138
Open AccessMitophagy in gastrointestinal tumors: mechanisms and new targets for immunotherapy
Gastrointestinal tumors (GITs), particularly gastric and colorectal cancers, are the leading causes of cancer-related deaths worldwide. Despite advances in screening technologies and the continuous development of treatments, which have improved early diagnosis and therapeutic interventions, the morbidity and mortality rates remain high, presenting a significant challenge to global public health. While existing treatments can extend patient survival to some degree, they are often accompanied by substantial side effects. In recent years, immunotherapy has yielded positive outcomes for some patients. However, the emergence of immune escape mechanisms has hindered treatment effectiveness. As a result, there is an urgent need for new therapeutic strategies that can address the limitations of current approaches. mitophagy, a key cellular process, has gained significant attention in cancer research. It plays an essential role in maintaining cellular energy balance and metabolic stability, and is intricately linked to crucial biological processes such as drug resistance, metastasis, invasion, and the tumor microenvironment. This article aims to provide a comprehensive review of the mechanisms underlying mitophagy, examining its role in gastrointestinal cancers, particularly in relation to cellular metabolism, apoptosis, drug resistance, metastasis, invasion, and the tumor microenvironment. Additionally, it will explore the potential of mitophagy as a therapeutic target and address current clinical challenges. It is hoped that this research will offer new insights and directions for the treatment of GITs.
- Open Access
- 1 January 2026
- Published by Innovation Press Co., Limited in The Innovation Life
- Vol. 4 (2) , 100179-1-100179-20
Gut microbiota-mucosal immunity crosstalk in the IBD microenvironment: Mechanistic insights into disease progression and intervention strategies
The gut microbiota forms a highly dynamic and multilayered ecological system that plays a pivotal role in maintaining mucosal immune homeostasis. When the “microbiota-immune regulatory” axis is perturbed in genetically susceptible individuals, antigen recognition and effector responses at the mucosal surface may be reshaped, thereby driving the onset and persistent progression of IBD. This review highlights the distinct patterns of microbe-immune interactions under physiological and pathological conditions, with particular focus on the key immunoregulatory events at different disease stages. In the early phase of IBD, adhesive and invasive bacterial strains and microbial dysbiosis can disrupt epithelial barriers, trigger aberrant innate immune activation, and induce chronic local inflammation. As the disease advances, T-cell polarization, tissue remodeling, and extraintestinal manifestations collectively sustain the inflammatory network and promote systemic damage. We further summarize emerging microbiota-based immunotherapeutic strategies-such as fecal microbiota transplantation, probiotics/prebiotics, targeted manipulation of specific bacterial taxa, bacteriophage therapy, and engineered probiotics-and their potential value and remaining clinical challenges in IBD management. Future work should integrate gut microbiota-immune crosstalk to identify clinically actionable targets and validate their biological and therapeutic significance through well-designed prospective studies.
- 1 January 2026
- Published by Innovation Press Co., Limited in The Innovation Life
- Vol. 4 (2) , 100179-1-100179-20
Open AccessGut microbiota-mucosal immunity crosstalk in the IBD microenvironment: Mechanistic insights into disease progression and intervention strategies
The gut microbiota forms a highly dynamic and multilayered ecological system that plays a pivotal role in maintaining mucosal immune homeostasis. When the “microbiota-immune regulatory” axis is perturbed in genetically susceptible individuals, antigen recognition and effector responses at the mucosal surface may be reshaped, thereby driving the onset and persistent progression of IBD. This review highlights the distinct patterns of microbe-immune interactions under physiological and pathological conditions, with particular focus on the key immunoregulatory events at different disease stages. In the early phase of IBD, adhesive and invasive bacterial strains and microbial dysbiosis can disrupt epithelial barriers, trigger aberrant innate immune activation, and induce chronic local inflammation. As the disease advances, T-cell polarization, tissue remodeling, and extraintestinal manifestations collectively sustain the inflammatory network and promote systemic damage. We further summarize emerging microbiota-based immunotherapeutic strategies-such as fecal microbiota transplantation, probiotics/prebiotics, targeted manipulation of specific bacterial taxa, bacteriophage therapy, and engineered probiotics-and their potential value and remaining clinical challenges in IBD management. Future work should integrate gut microbiota-immune crosstalk to identify clinically actionable targets and validate their biological and therapeutic significance through well-designed prospective studies.